{"total": 2, "data": [{"other_ids": null, "amendment_date": null, "keywords": null, "dcp_id": null, "interventional_model": null, "lead_org": "M D Anderson Cancer Center", "eligibility": {"unstructured": [{"inclusion_indicator": true, "display_order": 1, "description": "Have volunteered to participate in institutional or national biobanks, mainly the UK Biobank and the Kaiser Permanente Research Bank, and those that have previously participated in studies that resulted in de-identified clinical and genetic data being make available on public archives, mainly the database of Genotypes and Phenotypes (dbGaP)"}, {"inclusion_indicator": true, "display_order": 2, "description": "No special populations (adults unable to consent, individuals not yet adults, pregnant women, or prisoners)"}], "structured": {"max_age": "999 Years", "max_age_number": 999, "min_age_unit": "Years", "max_age_unit": "Years", "max_age_in_years": 999, "gender": "BOTH", "min_age": "0 Years", "accepts_healthy_volunteers": true, "min_age_number": 0, "min_age_in_years": 0}}, "sites": [{"org_state_or_province": "TX", "contact_name": "Kevin Nead", "contact_phone": "713-563-5155", "recruitment_status_date": "2020-02-13", "org_address_line_2": null, "org_va": false, "org_address_line_1": "1515 Holcombe Boulevard", "org_tty": null, "org_family": "MD Anderson Cancer Center", "org_postal_code": "77030", "contact_email": "ktnead@mdanderson.org", "recruitment_status": "ACTIVE", "org_city": "Houston", "org_email": "askmdanderson@mdanderson.org", "org_country": "United States", "org_fax": null, "org_phone": "877-632-6789", "org_name": "M D Anderson Cancer Center", "org_coordinates": {"lon": -95.4026, "lat": 29.7059}}], "completion_date_type_code": "ANTICIPATED", "detail_description": "PRIMARY OBJECTIVE:\r\nI. To use a Mendelian randomization study design to determine whether genetically predicted decreased testosterone levels are associated with an increased risk of dementia.\r\n\r\nSECONDARY OBJECTIVE:\r\nI. To examine whether genetically predicted decreased testosterone levels are associated with worse cognitive function and adverse mental health outcomes.\r\n\r\nOUTLINE:\r\nPatients' records from institutional or national biobanks are reviewed.", "official_title": "Evaluation of a Causal Association between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes: A Mendelian Randomization Analysis", "_phase_sort_order": 7, "collaborators": null, "associated_studies": null, "outcome_measures": [{"time_frame": "Up to 2 years", "name": "Anxiety", "description": "Association between low testosterone levels and anxiety will be examined. Will construct a weighted genetic risk score based on the strength of each variant\u2019s association with testosterone levels in published datasets. The results of the weighted method will be scaled per standard deviation (SD) of testosterone levels so that effect sizes represent the odds ratio of the outcome (e.g. dementia) per genetically predicted SD decrease in testosterone levels. Will also utilize risk scores with less stringent significance thresholds in secondary analyses (P < 5 x 10\u20136).", "type_code": "SECONDARY"}, {"time_frame": "Up to 2 years", "name": "Association between germline genetic predictors (single nucleotide variants) of lower testosterone levels and dementia risk", "description": "Will utilize genetic variants associated with testosterone levels at genome-wide statistical significance thresholds (P < 5 x 10\u20138) in published meta-analyses. Will additionally conduct a genome-wide association study with testosterone values in the UK Biobank. Will construct a weighted genetic risk score based on the strength of each variant\u2019s association with testosterone levels in published datasets. The results of the weighted method will be scaled per standard deviation (SD) of testosterone levels so that effect sizes represent the odds ratio of the outcome (e.g. dementia) per genetically predicted SD decrease in testosterone levels. Will also utilize risk scores with less stringent significance thresholds in secondary analyses (P < 5 x 10\u20136).", "type_code": "PRIMARY"}, {"time_frame": "Up to 2 years", "name": "Cognitive/mental health", "description": "Association between low testosterone levels and cognitive/mental health will be examined. Will construct a weighted genetic risk score based on the strength of each variant\u2019s association with testosterone levels in published datasets. The results of the weighted method will be scaled per standard deviation (SD) of testosterone levels so that effect sizes represent the odds ratio of the outcome (e.g. dementia) per genetically predicted SD decrease in testosterone levels. Will also utilize risk scores with less stringent significance thresholds in secondary analyses (P < 5 x 10\u20136).", "type_code": "SECONDARY"}, {"time_frame": "Up to 2 years", "name": "Depression", "description": "Association between low testosterone levels and depression will be examined. Will construct a weighted genetic risk score based on the strength of each variant\u2019s association with testosterone levels in published datasets. The results of the weighted method will be scaled per standard deviation (SD) of testosterone levels so that effect sizes represent the odds ratio of the outcome (e.g. dementia) per genetically predicted SD decrease in testosterone levels. Will also utilize risk scores with less stringent significance thresholds in secondary analyses (P < 5 x 10\u20136).", "type_code": "SECONDARY"}], "phase": "NA", "central_contact": {"phone": null, "name": null, "type": null, "email": null}, "primary_purpose": "OTHER", "number_of_arms": null, "_study_protocol_type_sort_order": 1, "nct_id": "NCT04743466", "biomarkers": null, "classification_code": null, "current_trial_status_date": "2020-02-13", "diseases": [{"inclusion_indicator": "TRIAL", "is_lead_disease": true, "synonyms": ["Malignant Solid Neoplasm"], "nci_thesaurus_concept_id": "C132146", "name": "Malignant Solid Tumor", "type": ["subtype"], "parents": ["C9305", "C9292"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": true, "synonyms": ["HEMOLYMPHORETICULAR TUMOR, MALIGNANT", "Hematologic Cancer", "Hematologic Malignancy", "Hematologic Neoplasm", "Hematological Neoplasm", "Hematopoietic Cancer", "Hematopoietic Neoplasm", "Hematopoietic Neoplasms Including Lymphomas", "Hematopoietic and Lymphoid Neoplasm", "Hematopoietic malignancy, NOS", "Malignant Hematologic Neoplasm", "Malignant Hematopoietic Neoplasm", "hematologic cancer"], "nci_thesaurus_concept_id": "C27134", "name": "Hematopoietic and Lymphoid Cell Neoplasm", "type": ["maintype"], "parents": ["C26323", "C35813", "C4741"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anxiety"], "nci_thesaurus_concept_id": "C2878", "name": "Anxiety Disorder", "type": ["subtype"], "parents": ["C2893"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["depression"], "nci_thesaurus_concept_id": "C2982", "name": "Depression", "type": ["subtype"], "parents": ["C92200"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Genetic Condition", "Hereditary Disease", "Hereditary Diseases", "Inherited Disease", "Molecular Disease"], "nci_thesaurus_concept_id": "C3101", "name": "Genetic Disorder", "type": ["subtype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Blood Disease", "Blood Disorder", "Hematologic Disorder", "Hematological Disorder"], "nci_thesaurus_concept_id": "C26323", "name": "Hematologic and Lymphocytic Disorder", "type": ["subtype"], "parents": ["C35814"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Disease by Site"], "nci_thesaurus_concept_id": "C27551", "name": "Disorder by Site", "type": ["subtype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": [], "nci_thesaurus_concept_id": "C7062", "name": "Neoplasm by Special Category", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Solid Neoplasm", "Solid Tumour", "Solid tumor, NOS", "solid tumor"], "nci_thesaurus_concept_id": "C9292", "name": "Solid Tumor", "type": ["maintype"], "parents": ["C7062"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Diagnosis", "Disease", "Disease or Disorder", "Disease or Disorder, Non-Neoplastic", "Diseases", "Diseases and Disorders", "Disorder", "Disorders", "condition", "disease", "disease term", "disease type", "disease_term", "disease_type", "disorder"], "nci_thesaurus_concept_id": "C2991", "name": "Other Disease", "type": ["maintype"], "parents": ["C7057"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Hematopoietic and Lymphoid System Disease"], "nci_thesaurus_concept_id": "C35814", "name": "Hematopoietic and Lymphoid System Disorder", "type": ["subtype"], "parents": ["C27551"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Diagnosis", "Disease", "Disease or Disorder", "Disease or Disorder, Non-Neoplastic", "Diseases", "Diseases and Disorders", "Disorder", "Disorders", "condition", "disease", "disease term", "disease type", "disease_term", "disease_type", "disorder"], "nci_thesaurus_concept_id": "C2991", "name": "Other Disease", "type": ["maintype"], "parents": ["C7057"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Mental Disorder", "Mental Dysfunction", "Mental Illness", "Psychiatric Disease"], "nci_thesaurus_concept_id": "C2893", "name": "Psychiatric Disorder", "type": ["subtype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Hematopoietic and Lymphoid System Tumor"], "nci_thesaurus_concept_id": "C35813", "name": "Hematopoietic and Lymphoid System Neoplasm", "type": ["subtype"], "parents": ["C35814", "C3263"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Tumor Morphology", "Tumor_Morphology"], "nci_thesaurus_concept_id": "C4741", "name": "Neoplasm by Morphology", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": [], "nci_thesaurus_concept_id": "C7057", "name": "Disease, Disorder or Finding", "type": [], "parents": []}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": [], "nci_thesaurus_concept_id": "C92200", "name": "Mood Disorder", "type": ["subtype"], "parents": ["C2893"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["CA", "Cancer", "Malignancy", "Malignant Growth", "Malignant Neoplastic Disease", "Malignant Tumor", "NEOPLASM, MALIGNANT", "Neoplasm, malignant", "Tumor, malignant, NOS", "Unclassified tumor, malignant", "cancer", "malignancy"], "nci_thesaurus_concept_id": "C9305", "name": "Malignant Neoplasm", "type": ["subtype"], "parents": ["C7062"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": [], "nci_thesaurus_concept_id": "C7057", "name": "Disease, Disorder or Finding", "type": [], "parents": []}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": [], "nci_thesaurus_concept_id": "C3263", "name": "Neoplasm by Site", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Neoplasia", "Neoplasm", "Neoplasm, NOS", "Neoplasms, NOS", "Neoplastic Disease", "Neoplastic Growth", "Tumor, NOS", "neoplasia", "neoplasm", "tumor"], "nci_thesaurus_concept_id": "C3262", "name": "Other Neoplasm", "type": ["maintype"], "parents": ["C2991"]}], "_primary_purpose_sort_order": 8, "protocol_id": "2019-1061", "active_sites_count": 1, "arms": [{"interventions": [{"inclusion_indicator": "TRIAL", "synonyms": ["Electronic Health Record Review"], "nci_thesaurus_concept_id": "C170821", "name": "Electronic Health Record Review", "description": null, "category": "other", "type": "Other", "parents": ["C42729"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C42729", "name": "Review", "description": "", "category": "none", "type": "Other", "parents": ["C25404"]}, {"inclusion_indicator": "TREE", "synonyms": ["Generic Action"], "nci_thesaurus_concept_id": "C25404", "name": "Action", "description": "", "category": "none", "type": "Other", "parents": ["C43431"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C43431", "name": "Activity", "description": "", "category": "none", "type": "Other", "parents": []}], "name": "Observational (biobank review)", "description": "Patients' records from institutional or national biobanks are reviewed.", "type": null}], "study_model_code": "CASE_CONTROL", "nci_id": "NCI-2020-13782", "why_study_stopped": null, "brief_summary": "This study evaluates the association between testosterone levels and risk of dementia and adverse mental health outcomes (e.g. depression and anxiety). It is not known whether low testosterone levels may be associated with an increased risk of dementia. Learning about the association between testosterone levels and risk of dementia may help determine the long-term effects of androgen deprivation therapy and may help improve quality of life.", "brief_title": "Evaluation of Association between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes", "study_population_description": "Individuals have volunteered to participate in institutional or national biobanks", "sampling_method_code": "NON_PROBABILITY_SAMPLE", "minimum_target_accrual_number": 700000, "_current_trial_status_sort_order": 0, "start_date": "2020-02-13", "record_verification_date": "2021-01-21", "ctep_id": null, "current_trial_status": "Active", "study_model_other_text": null, "masking": {"role_caregiver": null, "masking": null, "role_investigator": null, "role_outcome_assessor": null, "role_subject": null, "allocation_code": null}, "acronym": null, "anatomic_sites": ["Multiple"], "ccr_id": null, "start_date_type_code": "ACTUAL", "principal_investigator": "Kevin Nead", "study_source": "Institutional", "completion_date": "2022-11-01", "study_subtype_code": "OBSERVATIONAL", "study_protocol_type": "Non-interventional"}, {"other_ids": null, "amendment_date": "2020-12-14T00:00:00", "keywords": null, "dcp_id": null, "interventional_model": "Single Group", "lead_org": "UNC Lineberger Comprehensive Cancer Center", "eligibility": {"unstructured": [{"inclusion_indicator": true, "display_order": 1, "description": "Able to provide informed consent"}, {"inclusion_indicator": true, "display_order": 2, "description": "Able to speak English"}, {"inclusion_indicator": true, "display_order": 3, "description": "Diagnosed with breast cancer, stages I-III"}, {"inclusion_indicator": true, "display_order": 4, "description": "Scheduled for adjuvant or neoadjuvant chemotherapy"}, {"inclusion_indicator": false, "display_order": 5, "description": "A history of adverse reaction to memantine"}, {"inclusion_indicator": false, "display_order": 6, "description": "Another cancer diagnosis with an estimated survival of less than five years"}, {"inclusion_indicator": false, "display_order": 7, "description": "Previous chemotherapy exposure"}, {"inclusion_indicator": false, "display_order": 8, "description": "Severe cognitive impairment, defined as Blessed Orientation Memory Concentration Test (BOMC) >= 11"}, {"inclusion_indicator": false, "display_order": 9, "description": "Pregnancy, confirmed by a negative pregnancy test within 30 days of study enrollment, or breastfeeding"}, {"inclusion_indicator": false, "display_order": 10, "description": "Current alcohol or drug abuse"}], "structured": {"max_age": "999 Years", "max_age_number": 999, "min_age_unit": "Years", "max_age_unit": "Years", "max_age_in_years": 999, "gender": "BOTH", "min_age": "18 Years", "accepts_healthy_volunteers": false, "min_age_number": 18, "min_age_in_years": 18}}, "sites": [{"org_state_or_province": "NC", "contact_name": "Zev Nakamura", "contact_phone": "984-974-3829", "recruitment_status_date": "2020-06-18", "org_address_line_2": "Lineberger Comprehensive Cancer Center Third Floor Administrative Tower CB 7295", "org_va": false, "org_address_line_1": "450 West Drive", "org_tty": null, "org_family": "UNC Lineberger Comprehensive Cancer Center", "org_postal_code": "27599", "contact_email": "zev_nakamura@med.unc.edu", "recruitment_status": "ACTIVE", "org_city": "Chapel Hill", "org_email": "cancerclinicaltrials@med.unc.edu", "org_country": "United States", "org_fax": null, "org_phone": null, "org_name": "UNC Lineberger Comprehensive Cancer Center", "org_coordinates": {"lon": -79.0561, "lat": 35.9134}}, {"org_state_or_province": "NC", "contact_name": "Megan Ann McNamara", "contact_phone": null, "recruitment_status_date": "2020-11-19", "org_address_line_2": null, "org_va": false, "org_address_line_1": "4420 Lake Boone Trail", "org_tty": null, "org_family": "UNC Lineberger Comprehensive Cancer Center", "org_postal_code": "27607", "contact_email": "Megan.Mcnamara@unchealth.unc.edu", "recruitment_status": "ACTIVE", "org_city": "Raleigh", "org_email": null, "org_country": "United States", "org_fax": null, "org_phone": "919-784-7209", "org_name": "Rex Cancer Center", "org_coordinates": {"lon": -78.7126, "lat": 35.8072}}], "completion_date_type_code": "ANTICIPATED", "detail_description": "PRIMARY OBJECTIVE:\r\nI. To compare changes in pre- to post-chemotherapy cognitive function, as measured by Delayed Matching to Sample Test (DMS) score, in our cohort of patients with breast cancer receiving memantine hydrochloride (memantine) to historical controls.\r\n\r\nSECONDARY OBJECTIVES\r\nI. To compare pre- to post-chemotherapy changes in all other objective and self-reported cognitive function measures.\r\nII. To examine associations between objective and self-reported cognitive function with depression, anxiety, fatigue, menopausal status, baseline intelligence quotient (IQ), and perceived cognitive effort, cross-sectionally pre- and post-chemotherapy.\r\nIII. To explore the impact of cognitive decline on health-related quality of life (HRQOL), functional status, depression, and anxiety.\r\nIV. To estimate the feasibility of conducting a clinical trial of memantine for attenuating cognitive decline in patients with breast cancer during chemotherapy.\r\nV. To describe the safety of administering memantine to patients with breast cancer during chemotherapy.\r\n\r\nEXPLORATORY OBJECTIVES:\r\nI. To compare pre- to 6 months post-chemotherapy changes in objective and self-reported cognitive function measures.\r\nII. To describe changes in depression, anxiety, fatigue, HRQOL, and functional status from pre- to 6 months post-chemotherapy.\r\n\r\nOUTLINE: Beginning within 4 weeks prior to the start of chemotherapy and 1 week after chemotherapy initiation, patients receive memantine orally (PO) once daily (QD) in week 1, PO twice daily (BID) in weeks 2-4 for up to 4 weeks post-chemotherapy. At baseline and post-chemotherapy, patients also complete a cognitive assessment over 70 minutes.", "official_title": "Memantine for Prevention of Cognitive Decline during Adjuvant or Neoadjuvant Chemotherapy in Patients with Breast Cancer", "_phase_sort_order": 2, "collaborators": null, "associated_studies": null, "outcome_measures": [{"time_frame": "Up to 4 weeks post-chemotherapy", "name": "Adherence to treatment", "description": "Defined as percentage of self-reported doses of prescribed memantine actually taken. Descriptive statistics will be used.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in anxiety", "description": "Assessed using PROMIS-Anxiety. Linear regression models will be used to cross-sectionally evaluate association with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in attention and working memory", "description": "Will be assessed by Digit Span. Linear regression modeling will describe the associations between pre- to post-chemotherapy cognitive changes with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and KPS.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in depression", "description": "Assessed using the PROMIS-Depression. Linear regression models will be used to cross-sectionally evaluate association with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in executive function", "description": "Will be assessed by One Touch Stockings of Cambridge Test (OTS).", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in fatigue", "description": "Assessed using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Linear regression models will be used to cross-sectionally evaluate association with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in functional status", "description": "Assessed using patient-reported Karnofsky Performance Status (KPS).", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in health-related quality of life", "description": "Assessed using FACT-G.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in menopausal status", "description": "Assessed using Hormonal Status Questionnaire and follicle stimulating hormone level.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in perceived cognitive effort", "description": "Assessed using National Aeronautics and Space Administration (NASA)-Task Load Index. Linear regression models will be used to cross-sectionally evaluate association with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in processing speed", "description": "Will be assessed by Rapid Visual Processing (RVP).", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in semantic fluency", "description": "Will be assessed by the Animal Naming Test (ANT). Linear regression modeling will describe the associations between pre- to post-chemotherapy cognitive changes with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and KPS.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 4 weeks  post-chemotherapy", "name": "Change in the pre- to post-chemotherapy Delayed Matching to Sample Test (DMS) score", "description": "Scores range from 0-100%, defined by the percent of correct answers on the memory test. The DMS will be quantified as percent correct at 12-second delay. A paired t-test will test if the change in DMS score from pre- to post-chemotherapy is statistically different from historical controls. Pre- to post-chemotherapy, as well as pre- to 6 months post-chemotherapy, changes in all other cognitive measures will also be evaluated using paired t-tests. Linear regression modeling will describe the associations between pre- to post-chemotherapy cognitive changes with post-chemotherapy depression and anxiety (Patient-Reported Outcomes Measurement Information System [PROMIS] PROMIS), health-related quality of life (HRQOL) (Functional Assessment of Cancer Therapy-General [FACT-G]), and Karnofsky performance status (KPS).", "type_code": "PRIMARY"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Change in verbal fluency", "description": "Will be assessed by the Controlled Oral Word Association (COWA) Test. Linear regression modeling will describe the associations between pre- to post-chemotherapy cognitive changes with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and KPS.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in FACIT-F", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in FACT-G", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in Patient-KPS", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in PROMIS-Anxiety", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in PROMIS-Depression", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in RVP", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Changes in self-reported cognitive measures", "description": "Will be assessed by PROMIS Cognitive Function. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of cognitive complaints. Linear regression modeling will describe the associations between pre- to post-chemotherapy cognitive changes with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and KPS.", "type_code": "SECONDARY"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the Animal Naming Test", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the COWA", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the digit span", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the DMS", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).Will be evaluated using paired t-tests.", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the HVLT-R", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the OTS", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 6 months post-chemotherapy", "name": "Changes in the PROMIS cognitive function", "description": "Linear regression models will be used to cross-sectionally evaluate associations between depression (PROMIS-D), anxiety (PROMIS-A), sleep (PROMIS-Sleep Disturbance), menopausal status, fatigue (FACIT-F), estimated pre-cancer IQ (WTAR), and cognitive effort (NASA-TLX) with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points. Linear regression modeling will describe the associations between pre- to  post-chemotherapy cognitive changes (DMS, HVLT-R, COWA, ANT, Digit Span, PROMIS) with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and performance status (KPS).", "type_code": "OTHER_PRE_SPECIFIED"}, {"time_frame": "Baseline up to 4 weeks post-chemotherapy", "name": "Changes in verbal learning and memory", "description": "Will assess changes in The Hopkins Verbal Learning Test-Revised. Linear regression modeling will describe the associations between pre- to post-chemotherapy cognitive changes with post-chemotherapy depression and anxiety (PROMIS), HRQOL (FACT-G), and KPS.", "type_code": "SECONDARY"}, {"time_frame": "Up to 4 weeks post-chemotherapy", "name": "Incidence of adverse events", "description": "Safety will be measured as the frequency of reported adverse events. Will tabulate all adverse events, the dose at which they occurred, and if they led to dosing delays or removal from the study.", "type_code": "SECONDARY"}, {"time_frame": "Baseline", "name": "Pre-cancer intelligence quotient (IQ)", "description": "Assessed using Wechsler Adult Test of Reading (WTAR). Linear regression models will be used to cross-sectionally evaluate association with both objective (DMS, HVLTR, COWA, ANT, Digit Span) and self-reported (PROMIS) measures of cognitive function at baseline and post-chemotherapy. Linear mixed effects models will evaluate associations across pre- and post- time points.", "type_code": "SECONDARY"}, {"time_frame": "Up to 4 weeks post-chemotherapy", "name": "Recruitment", "description": "Defined as the percentage of invited patients who enroll. Descriptive statistics will be used.", "type_code": "SECONDARY"}, {"time_frame": "Up to 4 weeks post-chemotherapy", "name": "Retention", "description": "Measured as attrition, defined as the percentage of enrolled patients who are not eligible for analysis of the primary outcome. Descriptive statistics will be used.", "type_code": "SECONDARY"}], "phase": "II", "central_contact": {"phone": null, "name": null, "type": null, "email": null}, "primary_purpose": "PREVENTION", "number_of_arms": 1, "_study_protocol_type_sort_order": 0, "nct_id": "NCT04033419", "biomarkers": null, "classification_code": null, "current_trial_status_date": "2020-06-18", "diseases": [{"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage I Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139535", "name": "Stage I Breast Cancer", "type": ["stage"], "parents": ["C139533"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IA Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139536", "name": "Stage IA Breast Cancer", "type": ["stage"], "parents": ["C139535"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage IB Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139537", "name": "Stage IB Breast Cancer", "type": ["stage"], "parents": ["C139535"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage II Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139538", "name": "Stage II Breast Cancer", "type": ["stage"], "parents": ["C139533"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139539", "name": "Stage IIA Breast Cancer", "type": ["stage"], "parents": ["C139538"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139540", "name": "Stage IIB Breast Cancer", "type": ["stage"], "parents": ["C139538"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage III Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139541", "name": "Stage III Breast Cancer", "type": ["stage"], "parents": ["C139533"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139542", "name": "Stage IIIA Breast Cancer", "type": ["stage"], "parents": ["C139541"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139543", "name": "Stage IIIB Breast Cancer", "type": ["stage"], "parents": ["C139541"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139544", "name": "Stage IIIC Breast Cancer", "type": ["stage"], "parents": ["C139541"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": true, "synonyms": ["Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage I Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139556", "name": "Stage I Breast Cancer", "type": ["stage"], "parents": ["C139554"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IA Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139557", "name": "Stage IA Breast Cancer", "type": ["stage"], "parents": ["C139556"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage IB Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139558", "name": "Stage IB Breast Cancer", "type": ["stage"], "parents": ["C139556"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage II Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139569", "name": "Stage II Breast Cancer", "type": ["stage"], "parents": ["C139554"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139571", "name": "Stage IIA Breast Cancer", "type": ["stage"], "parents": ["C139569"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139572", "name": "Stage IIB Breast Cancer", "type": ["stage"], "parents": ["C139569"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage III Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139582", "name": "Stage III Breast Cancer", "type": ["stage"], "parents": ["C139554"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139583", "name": "Stage IIIA Breast Cancer", "type": ["stage"], "parents": ["C139582"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139584", "name": "Stage IIIB Breast Cancer", "type": ["stage"], "parents": ["C139582"]}, {"inclusion_indicator": "TRIAL", "is_lead_disease": false, "synonyms": ["Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139585", "name": "Stage IIIC Breast Cancer", "type": ["stage"], "parents": ["C139582"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage I Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139535", "name": "Stage I Breast Cancer", "type": ["stage"], "parents": ["C139533"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Breast Carcinoma by AJCC v8 Stage"], "nci_thesaurus_concept_id": "C139532", "name": "Breast Cancer by AJCC v8 Stage", "type": ["stage"], "parents": ["C4872"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Breast Carcinoma by AJCC v8 Stage"], "nci_thesaurus_concept_id": "C139532", "name": "Breast Cancer by AJCC v8 Stage", "type": ["stage"], "parents": ["C4872"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage III Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139541", "name": "Stage III Breast Cancer", "type": ["stage"], "parents": ["C139533"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["CA", "Cancer", "Malignancy", "Malignant Growth", "Malignant Neoplastic Disease", "Malignant Tumor", "NEOPLASM, MALIGNANT", "Neoplasm, malignant", "Tumor, malignant, NOS", "Unclassified tumor, malignant", "cancer", "malignancy"], "nci_thesaurus_concept_id": "C9305", "name": "Malignant Neoplasm", "type": ["subtype"], "parents": ["C7062"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["CA", "Cancer", "Malignancy", "Malignant Growth", "Malignant Neoplastic Disease", "Malignant Tumor", "NEOPLASM, MALIGNANT", "Neoplasm, malignant", "Tumor, malignant, NOS", "Unclassified tumor, malignant", "cancer", "malignancy"], "nci_thesaurus_concept_id": "C9305", "name": "Malignant Neoplasm", "type": ["subtype"], "parents": ["C7062"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Neoplasia", "Neoplasm", "Neoplasm, NOS", "Neoplasms, NOS", "Neoplastic Disease", "Neoplastic Growth", "Tumor, NOS", "neoplasia", "neoplasm", "tumor"], "nci_thesaurus_concept_id": "C3262", "name": "Other Neoplasm", "type": ["maintype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Disease by Site"], "nci_thesaurus_concept_id": "C27551", "name": "Disorder by Site", "type": ["subtype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Neoplasia", "Neoplasm", "Neoplasm, NOS", "Neoplasms, NOS", "Neoplastic Disease", "Neoplastic Growth", "Tumor, NOS", "neoplasia", "neoplasm", "tumor"], "nci_thesaurus_concept_id": "C3262", "name": "Other Neoplasm", "type": ["maintype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": [], "nci_thesaurus_concept_id": "C7062", "name": "Neoplasm by Special Category", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Disease by Site"], "nci_thesaurus_concept_id": "C27551", "name": "Disorder by Site", "type": ["subtype"], "parents": ["C2991"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Breast Tumor", "Neoplasm of Breast", "Neoplasm of the Breast", "Tumor of Breast", "Tumor of the Breast"], "nci_thesaurus_concept_id": "C2910", "name": "Breast Neoplasm", "type": ["subtype"], "parents": ["C26709", "C3263"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Breast Tumor", "Neoplasm of Breast", "Neoplasm of the Breast", "Tumor of Breast", "Tumor of the Breast"], "nci_thesaurus_concept_id": "C2910", "name": "Breast Neoplasm", "type": ["subtype"], "parents": ["C26709", "C3263"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": [], "nci_thesaurus_concept_id": "C7062", "name": "Neoplasm by Special Category", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Breast Carcinoma", "Breast cancer, NOS", "Cancer of Breast", "Cancer of the Breast", "Carcinoma of Breast", "Carcinoma of the Breast", "Mammary Carcinoma", "breast cancer"], "nci_thesaurus_concept_id": "C4872", "name": "Breast Cancer", "type": ["maintype"], "parents": ["C2916", "C9335"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage II Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139538", "name": "Stage II Breast Cancer", "type": ["stage"], "parents": ["C139533"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Breast Carcinoma", "Breast cancer, NOS", "Cancer of Breast", "Cancer of the Breast", "Carcinoma of Breast", "Carcinoma of the Breast", "Mammary Carcinoma", "breast cancer"], "nci_thesaurus_concept_id": "C4872", "name": "Breast Cancer", "type": ["maintype"], "parents": ["C2916", "C9335"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["CARCINOMA, MALIGNANT", "Carcinoma", "Carcinoma, NOS", "Epithelial Carcinoma", "Epithelial tumor, malignant", "Epithelioma Malignant", "Malignant Epithelial Neoplasm", "Malignant Epithelial Tumor", "Malignant Epithelioma", "carcinoma", "epithelial carcinoma"], "nci_thesaurus_concept_id": "C2916", "name": "Other Carcinoma", "type": ["maintype"], "parents": ["C3709", "C9305"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["CARCINOMA, MALIGNANT", "Carcinoma", "Carcinoma, NOS", "Epithelial Carcinoma", "Epithelial tumor, malignant", "Epithelioma Malignant", "Malignant Epithelial Neoplasm", "Malignant Epithelial Tumor", "Malignant Epithelioma", "carcinoma", "epithelial carcinoma"], "nci_thesaurus_concept_id": "C2916", "name": "Other Carcinoma", "type": ["maintype"], "parents": ["C3709", "C9305"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Breast Disease", "Breast Diseases"], "nci_thesaurus_concept_id": "C26709", "name": "Breast Disorder", "type": ["subtype"], "parents": ["C27551"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Breast Disease", "Breast Diseases"], "nci_thesaurus_concept_id": "C26709", "name": "Breast Disorder", "type": ["subtype"], "parents": ["C27551"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Breast Cancer by AJCC v8 Prognostic Stage Group", "Breast Carcinoma by AJCC v8 Prognostic Stage"], "nci_thesaurus_concept_id": "C139554", "name": "Breast Cancer by AJCC v8 Prognostic Stage", "type": ["stage"], "parents": ["C139532"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Breast Cancer by AJCC v8 Prognostic Stage Group", "Breast Carcinoma by AJCC v8 Prognostic Stage"], "nci_thesaurus_concept_id": "C139554", "name": "Breast Cancer by AJCC v8 Prognostic Stage", "type": ["stage"], "parents": ["C139532"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Breast Carcinoma by AJCC v8 Anatomic Stage"], "nci_thesaurus_concept_id": "C139533", "name": "Breast Cancer by AJCC v8 Anatomic Stage", "type": ["stage"], "parents": ["C139532"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Tumor Morphology", "Tumor_Morphology"], "nci_thesaurus_concept_id": "C4741", "name": "Neoplasm by Morphology", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": [], "nci_thesaurus_concept_id": "C7057", "name": "Disease, Disorder or Finding", "type": [], "parents": []}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Epithelial Neoplasms, NOS", "Epithelioma", "Epithelioma, malignant"], "nci_thesaurus_concept_id": "C3709", "name": "Epithelial Neoplasm", "type": ["subtype"], "parents": ["C4741"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Tumor Morphology", "Tumor_Morphology"], "nci_thesaurus_concept_id": "C4741", "name": "Neoplasm by Morphology", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Epithelial Neoplasms, NOS", "Epithelioma", "Epithelioma, malignant"], "nci_thesaurus_concept_id": "C3709", "name": "Epithelial Neoplasm", "type": ["subtype"], "parents": ["C4741"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": [], "nci_thesaurus_concept_id": "C7057", "name": "Disease, Disorder or Finding", "type": [], "parents": []}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage I Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139556", "name": "Stage I Breast Cancer", "type": ["stage"], "parents": ["C139554"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage II Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139569", "name": "Stage II Breast Cancer", "type": ["stage"], "parents": ["C139554"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Malignant Breast Tumor", "Malignant Neoplasm of Breast", "Malignant Neoplasm of the Breast", "Malignant Tumor of Breast", "Malignant Tumor of the Breast"], "nci_thesaurus_concept_id": "C9335", "name": "Malignant Breast Neoplasm", "type": ["subtype"], "parents": ["C2910", "C9305"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Malignant Breast Tumor", "Malignant Neoplasm of Breast", "Malignant Neoplasm of the Breast", "Malignant Tumor of Breast", "Malignant Tumor of the Breast"], "nci_thesaurus_concept_id": "C9335", "name": "Malignant Breast Neoplasm", "type": ["subtype"], "parents": ["C2910", "C9305"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage III Breast Carcinoma AJCC v8"], "nci_thesaurus_concept_id": "C139582", "name": "Stage III Breast Cancer", "type": ["stage"], "parents": ["C139554"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": ["Diagnosis", "Disease", "Disease or Disorder", "Disease or Disorder, Non-Neoplastic", "Diseases", "Diseases and Disorders", "Disorder", "Disorders", "condition", "disease", "disease term", "disease type", "disease_term", "disease_type", "disorder"], "nci_thesaurus_concept_id": "C2991", "name": "Other Disease", "type": ["maintype"], "parents": ["C7057"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": ["Diagnosis", "Disease", "Disease or Disorder", "Disease or Disorder, Non-Neoplastic", "Diseases", "Diseases and Disorders", "Disorder", "Disorders", "condition", "disease", "disease term", "disease type", "disease_term", "disease_type", "disorder"], "nci_thesaurus_concept_id": "C2991", "name": "Other Disease", "type": ["maintype"], "parents": ["C7057"]}, {"inclusion_indicator": "TREE", "is_lead_disease": false, "synonyms": [], "nci_thesaurus_concept_id": "C3263", "name": "Neoplasm by Site", "type": ["subtype"], "parents": ["C3262"]}, {"inclusion_indicator": "TREE", "is_lead_disease": true, "synonyms": [], "nci_thesaurus_concept_id": "C3263", "name": "Neoplasm by Site", "type": ["subtype"], "parents": ["C3262"]}], "_primary_purpose_sort_order": 3, "protocol_id": "LCCC1921", "active_sites_count": 2, "arms": [{"interventions": [{"inclusion_indicator": "TRIAL", "synonyms": ["Questionnaire Administration"], "nci_thesaurus_concept_id": "C64253", "name": "Questionnaire Administration", "description": null, "category": "other", "type": "Other", "parents": ["C64255"]}, {"inclusion_indicator": "TRIAL", "synonyms": ["Namenda", "Memantine Hydrochloride"], "nci_thesaurus_concept_id": "C47601", "name": "Memantine Hydrochloride", "description": "The hydrochloride salt of memantine, a low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. Memantine is also a 5-hydroxytryptamine  type 3 (5HT3) receptor and  nicotinic receptor antagonist. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional", "category": "agent", "type": "Drug", "parents": ["C38149"]}, {"inclusion_indicator": "TRIAL", "synonyms": ["Quality of Life Assessment", "Quality-of-Life Assessment"], "nci_thesaurus_concept_id": "C15584", "name": "Quality-of-Life Assessment", "description": null, "category": "other", "type": "Other", "parents": ["C15747"]}, {"inclusion_indicator": "TRIAL", "synonyms": ["Cognitive Assessment"], "nci_thesaurus_concept_id": "C62736", "name": "Cognitive Assessment", "description": null, "category": "other", "type": "Procedure/Surgery", "parents": ["C25305"]}, {"inclusion_indicator": "TREE", "synonyms": ["Informational Intervention"], "nci_thesaurus_concept_id": "C64255", "name": "Informational Intervention", "description": "", "category": "none", "type": "Other", "parents": ["C63474"]}, {"inclusion_indicator": "TREE", "synonyms": ["Behavioral, Psychological or Informational Intervention"], "nci_thesaurus_concept_id": "C63474", "name": "Behavioral, Psychological or Informational Intervention", "description": "", "category": "none", "type": "Other", "parents": ["C25218"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C25218", "name": "Intervention or Procedure", "description": "", "category": "none", "type": "Other", "parents": ["C16203"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C16203", "name": "Clinical or Research Activity", "description": "", "category": "none", "type": "Other", "parents": ["C43431"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C43431", "name": "Activity", "description": "", "category": "none", "type": "Other", "parents": []}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C38149", "name": "Antiparkinsonian Agent", "description": "", "category": "agent category", "type": "Drug", "parents": ["C78272"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C78272", "name": "Agent Affecting Nervous System", "description": "", "category": "agent category", "type": "Drug", "parents": ["C1909"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C1909", "name": "Pharmacologic Substance", "description": "", "category": "agent category", "type": "Drug", "parents": ["C1908"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C1908", "name": "Drug, Food, Chemical or Biomedical Material", "description": "", "category": "agent category", "type": "Drug", "parents": []}, {"inclusion_indicator": "TREE", "synonyms": ["Supportive Therapy", "Symptom Management", "Therapy, Supportive", "Supportive Care"], "nci_thesaurus_concept_id": "C15747", "name": "Supportive Care", "description": "", "category": "none", "type": "Other", "parents": ["C49236"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C49236", "name": "Therapeutic Procedure", "description": "", "category": "none", "type": "Other", "parents": ["C25218"]}, {"inclusion_indicator": "TREE", "synonyms": ["Exam", "Examination", "Medical Assessment", "Medical Exam", "Medical Inspection", "Medical Examination"], "nci_thesaurus_concept_id": "C25305", "name": "Medical Examination", "description": "", "category": "none", "type": "Procedure/Surgery", "parents": ["C18020"]}, {"inclusion_indicator": "TREE", "synonyms": [], "nci_thesaurus_concept_id": "C18020", "name": "Diagnostic Procedure", "description": "", "category": "none", "type": "Procedure/Surgery", "parents": ["C25218"]}], "name": "Prevention (memantine, cognitive assessment, surveys)", "description": "Beginning within 4 weeks prior to the start of chemotherapy and 1 week after chemotherapy initiation, patients receive memantine PO QD in week 1, PO BID in weeks 2-4 for up to 4 weeks post-chemotherapy. At baseline and post-chemotherapy, patients also complete a cognitive assessment over 70 minutes.", "type": "EXPERIMENTAL"}], "study_model_code": null, "nci_id": "NCI-2020-08189", "why_study_stopped": null, "brief_summary": "This phase II trial studies whether memantine, a medication commonly used for dementia, may lessen chemotherapy-related cognitive changes, also known as ''chemobrain,'' experienced by some patients receiving treatment for breast cancer. Cancer-related cognitive change refers to memory and concentration problems that can occur with cancer and cancer treatments. Memantine blocks the uptake of calcium by certain brain cells and decreases abnormal activity in the brain. Giving memantine may prevent chemotherapy-related cognitive decline, improve quality of life, physical function, and mental health in patients with breast cancer.", "brief_title": "Memantine for the Prevention of Cognitive Decline during Chemotherapy in Patients with Breast Cancer", "study_population_description": null, "sampling_method_code": null, "minimum_target_accrual_number": 56, "_current_trial_status_sort_order": 0, "start_date": "2019-09-03", "record_verification_date": "2021-05-21", "ctep_id": null, "current_trial_status": "Active", "study_model_other_text": null, "masking": {"role_caregiver": null, "masking": null, "role_investigator": null, "role_outcome_assessor": null, "role_subject": null, "allocation_code": "NA"}, "acronym": null, "anatomic_sites": ["Breast"], "ccr_id": null, "start_date_type_code": "ACTUAL", "principal_investigator": "Zev Nakamura", "study_source": "Institutional", "completion_date": "2022-06-30", "study_subtype_code": null, "study_protocol_type": "Interventional"}]}